Teva Pharmaceutical Industries Ltd. (TEVA) said that the U.S. Food and Drug Administration has granted final approval for the company's Abbreviated New Drug Application to market its generic version of Tap Pharmaceutical's proton pump inhibitor Prevacid or lansoprazole) Delayed-Release Capsules, 15 mg and 30 mg. The company said the customers would begin receiving product on November 11, 2009.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is a generic pharmaceutical company.
For comments and feedback: editorial@rttnews.com